Targeted Delivery of RNAi Therapeutics for Cancer Therapy

• Fire A , XuS, MontgomeryMK, KostasSA, DriverSE, MelloCC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.Nature391, 806–811 (1998).
   PubMed Web of Science ®Google Scholar
• Zamore PD , TuschlT, SharpPA, BartelDP: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.Cell101, 25–339 (2000).
   PubMed Web of Science ®Google Scholar
• Whitehead KA , LangerR, AndersonDG: Knocking down barriers: advances in siRNA delivery.Nat. Rev. Drug Discov.8, 129–138 (2009).
   PubMed Web of Science ®Google Scholar
• Harris JM , ChessRB: Effect of pegylation on pharmaceuticals.Nat. Rev. Drug Discov.2, 214–221 (2003).
   PubMed Web of Science ®Google Scholar
• Xu Y , SzokaFC Jr: Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry35, 5616–5623 (1996).
   PubMed Web of Science ®Google Scholar
• Hafez IM , MaurerN, CullisPR: On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids.Gene Ther.8, 1188–1196 (2001).
   PubMed Web of Science ®Google Scholar
• Semple SC , AkincA, ChenJet al.: Rational design of cationic lipids for siRNA delivery.Nat. Biotechnol.28, 172–176 (2010).
   PubMed Web of Science ®Google Scholar
• Akinc A , QuerbesW, DeSet al.: Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.Mol. Ther.18, 1357–1364 (2010).
   PubMed Web of Science ®Google Scholar
• Jeffs LB , PalmerLR, AmbegiaEG, GiesbrechtC, EwanickS, MacLachlanI: A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA.Pharm. Res.22, 362–372 (2005).
   PubMed Web of Science ®Google Scholar
• Zimmermann TS , LeeAC, AkincAet al.: RNAi-mediated gene silencing in non-human primates.Nature441, 111–114 (2006).
   PubMed Web of Science ®Google Scholar
• Akinc A , ZumbuehlA, GoldbergMet al.: A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.Nat. Biotechnol.26, 561–569 (2008).
   PubMed Web of Science ®Google Scholar
• Akinc A , GoldbergM, QinJet al.: Development of lipidoid-siRNA formulations for systemic delivery to the liver.Mol. Ther17, 872–879 (2009).
   PubMed Web of Science ®Google Scholar
• Love KT , MahonKP, LevinsCGet al.: Lipid-like materials for low-dose, in vivo gene silencing.Proc. Natl Acad. Sci. USA 107, 1864–1869 (2010).
   PubMed Web of Science ®Google Scholar
• Judge AD , RobbinsM, TavakoliIet al.: Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.J. Clin. Invest.119, 661–673 (2009).
   PubMed Web of Science ®Google Scholar
• Li S , HuangL. In vivo gene transfer via intravenous administration of cationic lipid–protamine–DNA (LPD) complexes. Gene Ther.4, 891–900 (1997).
   PubMed Web of Science ®Google Scholar
• Li S , RizzoMA, BhattacharyaS, HuangL: Characterization of cationic lipid–protamine–DNA (LPD) complexes for intravenous gene delivery.Gene Ther.5, 930–937 (1998).
   PubMed Web of Science ®Google Scholar
• Li SD , ChenYC, HackettMJ, HuangL: Tumor-targeted delivery of siRNA by self-assembled nanoparticles.Mol. Ther.16, 163–169 (2008).
   PubMed Web of Science ®Google Scholar
• Li SD , HuangL: Nanoparticles evading the reticuloendothelial system: role of the supported bilayer.Biochim. Biophys. Acta1788, 2259–2266 (2009).
   PubMed Web of Science ®Google Scholar
• Li SD , ChonoS, HuangL: Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA.Mol. Ther.16, 942–946 (2008).
   PubMed Web of Science ®Google Scholar
• Chono S , LiSD, ConwellCC, HuangL: An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor.J. Control. Release131, 64–69 (2008).
   PubMed Web of Science ®Google Scholar
• Li J , ChenYC, TsengYC, MozumdarS, HuangL: Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery.J. Control. Release142, 416–421 (2010).
   PubMed Web of Science ®Google Scholar
• Landen CN , Jr, Chavez-Reyes A, Bucana C et al.: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res.65, 6910–6918 (2005).
   PubMed Web of Science ®Google Scholar
• Kim SH , JeongJH, LeeSH, KimSW, ParkTG: PEG conjugated VEGF siRNA for anti-angiogenic gene therapy.J. Control. Release116, 123–129 (2006).
   PubMed Web of Science ®Google Scholar
• Han HD , MangalaLS, LeeJWet al.: Targeted gene silencing using RGD-labeled chitosan nanoparticles.Clin. Cancer Res.16, 3910–3922 (2010).
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S , HeidelJD, BartlettDW, DavisME, TricheTJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing‘s sarcoma.Cancer Res.65, 8984–8992 (2005).
   PubMed Web of Science ®Google Scholar
• Davis ME , ZuckermanJE, ChoiCHet al.: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.Nature464, 1067–1070 (2010).
   PubMed Web of Science ®Google Scholar
• Rozema DB , LewisDL, WakefieldDHet al.: Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes.Proc. Natl Acad. Sci. USA 104, 12982–12987 (2007).
   PubMed Web of Science ®Google Scholar
• Musacchio T , VazeO, D‘SouzaG, TorchilinVP: Effective stabilization and delivery of siRNA: reversible siRNA–phospholipid conjugate in nanosized mixed polymeric micelles.Bioconjug. Chem.21, 1530–1536 (2010).
   PubMed Web of Science ®Google Scholar
• Song E , ZhuP, LeeSKet al.: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.Nat. Biotechnol.23, 709–717 (2005).
   PubMed Web of Science ®Google Scholar
• Takeshita F , MinakuchiY, NagaharaSet al.: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.Proc. Natl Acad. Sci. USA 102, 12177–12182 (2005).
   PubMed Web of Science ®Google Scholar
• Yan W , ChenW, HuangL: Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine.J. Control. Release130, 22–28 (2008).
   PubMed Web of Science ®Google Scholar
• Fedorov Y , AndersonEM, BirminghamAet al.: Off-target effects by siRNA can induce toxic phenotype.RNA12, 1188–1196 (2006).
   PubMed Web of Science ®Google Scholar
• Jackson AL , BurchardJ, LeakeDet al.: Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing.RNA12, 1197–1205 (2006).
   PubMed Web of Science ®Google Scholar

Websites

• Clinicaltrials.gov: Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of liposomal siRNA in Subjects with high cholesterol (2010) http://clinicaltrials.gov/ct2/show/NCT00927459?term=siRNA&rank=10
   Google Scholar
• Clinicaltrials.gov: Dose escalation trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous ALN-VSP02 in patients with advanced solid tumors with liver involvement (2010) http://clinicaltrials.gov/ct2/show/NCT00882180?term=Alnylam&rank=3
   Google Scholar